Bode et al. (32) showed in a rat model of HFpEF related to metabolic syndrome that rats that received the SGLT2 inhibitor Sotagliflozin exhibited improved metabolic left atrial remodeling and arrhythmia characteristics. Here, SLC5A2 is linked to metabolic syndrome.